Product
CT-L01
Aliases
CT-L01 12.5/1,000 mg
3 clinical trials
1 indication
Indication
HealthyClinical trial
A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluate Bioequivalence After Co-administration of ALO 12.5 mg and MET XR 500 mg or Administration of CT-L01 12.5/500 mg in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-07-05
Clinical trial
A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluate Bioequivalence After Co-administration of ALO 25 mg and MET XR 1,000 mg or Administration of CT-L01 25/1,000 mg in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-06-21
Clinical trial
A Phase I, Randomized, Open-Label, Single-Dose, Crossover Study to Evaluate Food Effect on the Pharmacokinetics and Safety of CT-L01 After Oral Administration in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-07-19